Iron-Oxide Nanocomposite for Cancer Cell Studies
Official patent title
Inhibition of cancer cell viability by nanocomposites of graphitic C3N4, Fe2O3, and MgAl2O4
Arabic title: تثبيط حيوية الخلايا السرطانية بواسطة مركبات نانوية من C.SUB.3.N.SUB.4. الجرافيتي وFe.SUB.2.O.SUB.3 وMgAl..SUB.2O.SUB.4
Invention
Invention
Problem
Cancer-cell screening needs candidate materials that can reduce malignant-cell viability, but activity must be distinguished from nonspecific toxicity. Translation requires evidence for selectivity, mechanism, exposure, and safety beyond cultured cells.
Why it matters
A reproducible in-vitro response can justify further preclinical study of an experimental nanocomposite, while remaining far short of a demonstrated cancer therapy.
Approach
The method contacts cancer cells with a g-C3N4/Fe2O3/MgAl2O4 nanocomposite in a 5–15:2–7:75–95 mass relationship at 7.5–500 µg/mL, with claimed growth inhibition of at least 85%.
Who may benefit
Potential beneficiaries include cancer-biology laboratories, nanomedicine researchers, drug-discovery teams, toxicologists, and advanced-material developers.
Potential value
The disclosure pairs a defined iron-oxide ternary nanocomposite with viability testing in HepG-2 and MCF-7 cell lines and detailed structural and porosity ranges.
Background
Background
Nanomaterials are investigated in oncology because composition, size, and surface chemistry can influence cell uptake and stress pathways. Iron oxides and carbon-based structures may offer useful physical or chemical properties, but killing cultured cancer cells can reflect general cytotoxicity rather than therapeutic selectivity. Meaningful development therefore requires comparisons with normal cells, mechanistic evidence, dose and exposure studies, and in-vivo safety and efficacy. This patent reports an iron-oxide, carbon-nitride, and magnesium-aluminate composite in cell-culture assays.
Technology overview
Technology overview
The composite combines g-C3N4, Fe2O3, and MgAl2O4, preferably near a 10:5:85 mass relationship. Reported material properties include 15–45 m²/g BET area, bimodal pores, and XRD/SAED phase information. HepG-2 liver-cancer and MCF-7 breast-cancer cells are contacted at specified concentration ranges, and the claims state at least 85% growth inhibition. The disclosure excludes several additives and process conditions. The biological evidence described is preclinical and in vitro.
Potential applications
Potential applications
- In-vitro cancer-cell research.
- Nanocomposite cytotoxicity screening.
- Preclinical mechanism and uptake studies.
- Lead discovery for experimental oncology materials.
Evidence-supported advantages
Evidence-supported advantages
- Defines the three-component composition range.
- Reports testing in two human cancer-cell lines.
- Includes detailed pore and crystal characterization.
- Uses iron oxide rather than a precious-metal component.
- Supports follow-on mechanistic screening.
Development stage
Development stage
Material characterization and in-vitro viability testing in cancer-cell lines are described; selectivity against normal cells, animal pharmacology, animal efficacy and safety, and clinical testing were not established. The development stage was not independently verified.
Commercial opportunity
Commercial opportunity
The invention is an early experimental lead, potentially relevant to oncology-screening and nanotoxicology partnerships. Progress needs independent assay replication, normal-cell controls, mechanistic and biodistribution studies, genotoxicity and immunotoxicity, animal efficacy and tolerability, formulation and administration development, scalable quality-controlled manufacture, and regulatory authorization before any human therapeutic use.
Patent classifications
Patent classifications
WIPO IPC
- A61K33/44Preparations for medical, dental or toiletry purposes
- A61K33/08Preparations for medical, dental or toiletry purposes
CPC
- A61K33/08Preparations for medical, dental or toiletry purposes
- A61K33/26Preparations for medical, dental or toiletry purposes
- A61K33/44Preparations for medical, dental or toiletry purposes
Inventors
Inventors
- First inventorMohamed Khairy Abdel Fattah Omran
- InventorBabiker Yagoub Elhadi Abdulkhair
Keywords
Keywords
- cancer cell viability
- iron oxide
- graphitic carbon nitride
- magnesium aluminate
- HepG-2
- MCF-7
- nanocomposite
- in vitro
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.